Genfit
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.8
- Today's High:
- $3.93
- Open Price:
- $3.86
- 52W Low:
- $3.28
- 52W High:
- $4.75
- Prev. Close:
- $3.9
- Volume:
- 46526
Company Statistics
- Market Cap.:
- $180.28 million
- Book Value:
- 1.902
- Revenue TTM:
- $26.25 million
- Operating Margin TTM:
- -105.3%
- Gross Profit TTM:
- $26.25 million
- Profit Margin:
- -90.37%
- Return on Assets TTM:
- -6.95%
- Return on Equity TTM:
- -22.21%
Company Profile
Genfit had its IPO on 2019-03-27 under the ticker symbol GNFT.
The company operates in the Healthcare sector and Biotechnology industry. Genfit has a staff strength of 148 employees.
Stock update
Shares of Genfit opened at $3.86 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.8 - $3.93, and closed at $3.84.
This is a -1.54% slip from the previous day's closing price.
A total volume of 46,526 shares were traded at the close of the day’s session.
In the last one week, shares of Genfit have increased by +11.63%.
Genfit's Key Ratios
Genfit has a market cap of $180.28 million, indicating a price to book ratio of 1.5757 and a price to sales ratio of 1.9135.
In the last 12-months Genfit’s revenue was $26.25 million with a gross profit of $26.25 million and an EBITDA of $-25884000. The EBITDA ratio measures Genfit's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Genfit’s operating margin was -105.3% while its return on assets stood at -6.95% with a return of equity of -22.21%.
In Q2, Genfit’s quarterly earnings growth was a positive 0% while revenue growth was a negative 82.8%.
Genfit’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.5 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Genfit’s profitability.
Genfit stock is trading at a EV to sales ratio of 0.3623 and a EV to EBITDA ratio of 0.5413. Its price to sales ratio in the trailing 12-months stood at 1.9135.
Genfit stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $215.54 million
- Total Liabilities
- $39.37 million
- Operating Cash Flow
- $-99500.00
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Genfit ended 2024 with $215.54 million in total assets and $0 in total liabilities. Its intangible assets were valued at $215.54 million while shareholder equity stood at $94.53 million.
Genfit ended 2024 with $0 in deferred long-term liabilities, $39.37 million in other current liabilities, 12459000.00 in common stock, $-361269000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $136.00 million and cash and short-term investments were $140.55 million. The company’s total short-term debt was $5,080,000 while long-term debt stood at $0.
Genfit’s total current assets stands at $158.46 million while long-term investments were $0 and short-term investments were $4.55 million. Its net receivables were $15.91 million compared to accounts payable of $14.85 million and inventory worth $4000.00.
In 2024, Genfit's operating cash flow was $-99500.00 while its capital expenditure stood at $0.
Comparatively, Genfit paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.84
- 52-Week High
- $4.75
- 52-Week Low
- $3.28
- Analyst Target Price
- $
Genfit stock is currently trading at $3.84 per share. It touched a 52-week high of $4.75 and a 52-week low of $4.75. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $3.71 and 200-day moving average was $4.02 The short ratio stood at 7.28 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 442.4% are held by institutions.
Frequently Asked Questions About Genfit
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.